ClinicalTrials.gg
CompletedNCT02170909Updated Aug 31, 2018

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

A Phase 1 interventional study of BIBR 1048 MS low dose and BIBR 1048 MS medium dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead (electrocardiogram), clinical laboratory tests

    • 1.1 No finding deviating from normal and of clinical relevance
    • 1.2 No evidence of a concomitant disease
  2. Age ≥ 20 and Age ≤ 45 years
  3. (BMI) ≥ 18 and ≤ 25 kg/m2
  4. Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
  5. Signed and dated written prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.

Exclusion criteria

Exclusion Criteria:

  1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use an adequate form of as well as having their female partner(s) use another form of contraception (if the woman possibly become pregnant) from the time of the single dose on Day 1 until Day 22-26 (end-of study examination)
  3. Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
  4. History of orthostatic hypotension, clinically significant current or past fainting spells or blackouts
  5. Chronic or relevant acute infections
  6. History of

    • allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic disease
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
  8. Use of acetylsalicylic acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) (cyclooxygenase-2 (COX-2) inhibitors excluded), coumadin like anticoagulants, chronic use of , heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
  9. Participation in another trial with an drug within three months prior to administration or during the trial
  10. Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
  11. Inability to refrain from smoking on trial days
  12. Alcohol abuse (more than 21unit/week; one unit was approximately half a pint of beer, a small glass of wine or one measure of spirits)
  13. History of drug abuse
  14. Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to end-of-study examination)
  15. Excessive physical activities (within one week prior to administration or during the trial and until end-of-study examination)
  16. Any laboratory value outside the reference range that was of clinical relevance
  17. Inability to comply with dietary regimen of study centre
  18. Known hypersensitivity to the drug or its
  19. History of any familial bleeding disorder
  20. \< 150000/μL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    BIBR 1048 MS low dose

    Drug: BIBR 1048 MS low dose

  • Experimental
    BIBR 1048 MS medium dose

    Drug: BIBR 1048 MS medium dose

  • Experimental
    BIBR 1048 MS high dose

    Drug: BIBR 1048 MS high dose

06

What researchers measure

Primary outcomes

  1. Change in vital signs

    Time frame: Baseline and up to day 26

  2. Change in 12-lead electrocardiogram (ECG)

    Time frame: Baseline and up to day 26

  3. Change in clinical laboratory tests

    Time frame: Baseline and up to day 26

  4. Occurence of adverse events

    Time frame: Up to day 26

Secondary outcomes

  1. Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT)

    Time frame: Day 1 and 12

  2. AUC from 0-24 hours for ecarin clotting time (ECT)

    Time frame: Day 1 and 12

  3. Change in thrombin time (TT)

    Time frame: Baseline and up to 72 hours after administration on day 1 and 12

  4. Change in prothrombin time (PT) expressed as international normalised ratio (INR)

    Time frame: Baseline and up to 72 hours after administration on day 1 and 12

  5. Maximum value of aPTT

    Time frame: Up to 72 hours after administration on day 1 and 12

  6. Maximum value of ECT

    Time frame: Up to 72 hours after administration on day 1 and 12

  7. Change in ECT

    Time frame: Baseline and up to 72 hours after administration on day 1 and 12

  8. Change in aPTT

    Time frame: Baseline and up to 72 hours after administration on day 1 and 12

  9. Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: Up to 72 hours after administration on day 1

  10. tmax (time from dosing to maximum measured concentration of the analyte in plasma)

    Time frame: Up to 72 hours after administration on day 1

  11. AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1)

    Time frame: Up to 72 hours after administration on day 1

  12. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)

    Time frame: Up to 72 hours after administration on day 1

  13. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: Up to 72 hours after administration on day 1

  14. λz (terminal rate constant in plasma)

    Time frame: Up to 72 hours after administration on day 1

  15. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: Up to 72 hours after administration on day 1

  16. MRTpo (mean residence time of the analyte in the body after po administration)

    Time frame: Up to 72 hours after administration on day 1

  17. CL/F (apparent clearance of the analyte in plasma following extravascular administration)

    Time frame: Up to 72 hours after administration on day 1

  18. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)

    Time frame: Up to 72 hours after administration on day 1

  19. Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)

    Time frame: Up to 72 hours after administration on day 1

  20. fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)

    Time frame: Up to 72 hours after administration on day 1

  21. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)

    Time frame: Up to 72 hours after administration on day 1

  22. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: Up to 72 hours after the last dose on day 12

  23. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)

    Time frame: Up to 72 hours after the last dose on day 12

  24. Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: Up to 72 hours after the last dose on day 12

  25. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: Up to 72 hours after the last dose on day 12

  26. λz,ss (terminal rate constant in plasma at steady state)

    Time frame: Up to 72 hours after the last dose on day 12

  27. t1/2,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: Up to 72 hours after the last dose on day 12

  28. MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)

    Time frame: Up to 72 hours after the last dose on day 12

  29. CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)

    Time frame: Up to 72 hours after the last dose on day 12

  30. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)

    Time frame: Up to 72 hours after the last dose on day 12

  31. Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2)

    Time frame: Up to 72 hours after the last dose on day 12

  32. fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2)

    Time frame: Up to 72 hours after the last dose on day 12

  33. CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state)

    Time frame: Up to 72 hours after the last dose on day 12

  34. Accumulation ratio RA,Cmax,7 based on Cmax

    Time frame: Day 6 to day 15

  35. Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups)

    Time frame: Day 6 to day 15

  36. Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups)

    Time frame: Day 6 to day 15

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Dec 2004
Primary completionActual
Jun 2005
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02170909
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Dec 2004
Primary completion
Jun 2005
Last update
Aug 31, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion